Display options
Cite
Dierks RM, Bruyère O, Reginster JY, et al. Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Expert Rev Pharmacoecon Outcomes Res. 2016;16(5):571-578doi: 10.1080/14737167.2016.1239534.
Dierks, R. M., Bruyère, O., Reginster, J. Y., & Richy, F. F. (2016). Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Expert review of pharmacoeconomics & outcomes research, 16(5), 571-578. https://doi.org/10.1080/14737167.2016.1239534
Dierks, Raphaela Marie Louisa, et al. "Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry." Expert review of pharmacoeconomics & outcomes research vol. 16,5 (2016): 571-578. doi: https://doi.org/10.1080/14737167.2016.1239534
Dierks RM, Bruyère O, Reginster JY, Richy FF. Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. Expert Rev Pharmacoecon Outcomes Res. 2016 Oct;16(5):571-578. doi: 10.1080/14737167.2016.1239534. Epub 2016 Oct 04. PMID: 27653356.
Copy Download .nbib Format: NLM
Share it on

Expert Rev Pharmacoecon Outcomes Res. 2016 Oct;16(5):571-578. doi: 10.1080/14737167.2016.1239534. Epub 2016 Oct 04.

Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry.

Expert review of pharmacoeconomics & outcomes research

Raphaela Marie Louisa Dierks, Olivier Bruyère, Jean-Yves Reginster, Florent-Frederic Richy

Affiliations

  1. a Department of Public Health, Faculty of Medicine, Epidemiology and Health Economics , Université de Liège , Liège , Belgium.

PMID: 27653356 DOI: 10.1080/14737167.2016.1239534

Abstract

INTRODUCTION: Technological innovations, new regulations, increasing costs of drug productions and new demands are only few key drivers of a projected alternation in the pharmaceutical industry. The purpose of this review is to understand the macro economic factors responsible for the business model revolution to possess a competitive advantage over market players. Areas covered: Existing literature on macro-economic factors changing the pharmaceutical landscape has been reviewed to present a clear image of the current market environment. Expert commentary: Literature shows that pharmaceutical companies are facing an architectural alteration, however the evidence on the rationale driving the transformation is outstanding. Merger & Acquisitions (M&A) deals and collaborations are headlining the papers. Q1 2016 did show a major slowdown in M&A deals by volume since 2013 (with deal cancellations of Pfizer and Allergan, or the downfall of Valeant), but pharmaceutical analysts remain confident that this shortfall was a consequence of the equity market volatility. It seems likely that the shift to an M&A model will become apparent during the remainder of 2016, with deal announcements of Abbott Laboratories, AbbVie and Sanofi worth USD 45billion showing the appetite of big pharma companies to shift from the fully vertical integrated business model to more horizontal business models.

Keywords: Macro-economic factors; business model; healthcare; pharmaceutical industry

MeSH terms

Publication Types